Interactions between bronchoalveolar lymphocytes and macrophages in heart-lung transplant recipients.

PubWeight™: 1.65‹?› | Rank: Top 3%

🔗 View Article (PMID 3932269)

Published in Hum Immunol on November 01, 1985

Authors

J J Fung, A Zeevi, C Kaufman, I L Paradis, J H Dauber, R L Hardesty, B Griffith, R J Duquesnoy

Articles by these authors

A flexible procedure for multiple cadaveric organ procurement. Surg Gynecol Obstet (1984) 10.33

Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76

Venous bypass in clinical liver transplantation. Ann Surg (1984) 7.04

The many faces of multivisceral transplantation. Surg Gynecol Obstet (1991) 6.89

Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet (1984) 5.74

Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancreas islet transplantation. Lancet (1994) 5.54

Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01

Intestinal transplantation in composite visceral grafts or alone. Ann Surg (1992) 4.96

Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology (1994) 4.32

Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18

Baboon-to-human liver transplantation. Lancet (1993) 4.01

Liver transplantation in the United States, 1999-2008. Am J Transplant (2010) 3.92

Systemic chimerism in human female recipients of male livers. Lancet (1992) 3.63

Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. Transplantation (1995) 3.63

Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. Transplant Proc (1991) 3.40

Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology (1991) 3.34

Translocation as a species conservation tool: status and strategy. Science (1989) 3.31

Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc (1990) 3.29

Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant (2010) 3.29

Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection. Nephron (1987) 3.26

Rejection of multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small-bowel and liver grafts. Surgery (1990) 3.18

Renal transplantation in baboons under FK 506. Surgery (1989) 3.17

The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14

Chimerism and donor-specific nonreactivity 27 to 29 years after kidney allotransplantation. Transplantation (1993) 3.13

Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci U S A (1990) 3.03

Heart-liver transplantation in a patient with familial hypercholesterolaemia. Lancet (1984) 2.91

Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg (2000) 2.91

Veno-venous bypass without systemic anticoagulation for transplantation of the human liver. Surg Gynecol Obstet (1985) 2.88

Functional characterization of infiltrating T lymphocytes in human hepatic allografts. Hum Immunol (1986) 2.84

Allospecificity of activated T cells grown from endomyocardial biopsies from heart transplant patients. Transplantation (1986) 2.82

Hematolymphoid cell trafficking, microchimerism, and GVH reactions after liver, bone marrow, and heart transplantation. Transplant Proc (1993) 2.81

Cadaveric small bowel and small bowel-liver transplantation in humans. Transplantation (1992) 2.75

Immunologic abnormalities in sarcoidosis. Ann Intern Med (1980) 2.66

Management of intestinal transplantation in humans. Transplant Proc (1992) 2.62

Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc (1990) 2.60

Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. Transplantation (1990) 2.59

Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. Transplant Proc (1991) 2.59

The prediction of risk of recurrence and time to recurrence of hepatocellular carcinoma after orthotopic liver transplantation: a pilot study. Hepatology (1997) 2.57

FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation (1994) 2.50

Pregnancy after liver transplantation under tacrolimus. Transplantation (1997) 2.50

Pharmacokinetics of FK 506: preclinical and clinical studies. Transplant Proc (1990) 2.48

Lessons learned in pediatric heart transplantation. Ann Thorac Surg (1989) 2.46

Comprehensive assessment and standardization of solid phase multiplex-bead arrays for the detection of antibodies to HLA. Am J Transplant (2013) 2.45

Prioritization and organ distribution for liver transplantation. JAMA (1994) 2.38

Clonal dominance among T-lymphocyte infiltrates in arthritis. Proc Natl Acad Sci U S A (1988) 2.36

The antibody crossmatch in liver transplantation. Surgery (1986) 2.33

The incidence, timing, and management of biliary tract complications after orthotopic liver transplantation. Ann Surg (1994) 2.32

Clinical intestinal transplantation: new perspectives and immunologic considerations. J Am Coll Surg (1998) 2.31

Differential survival of hamster-to-rat liver and cardiac xenografts under FK 506 immunosuppression. Transplant Proc (1991) 2.28

Assessment of five-year experience with abdominal organ cluster transplantation. J Am Coll Surg (1995) 2.25

Should HLA mismatch acceptability for sensitized transplant candidates be determined at the high-resolution rather than the antigen level? Am J Transplant (2015) 2.24

Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg (1999) 2.22

Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant (2006) 2.22

Cardiac transplantation with cyclosporin A and prednisone. Ann Surg (1982) 2.21

Human islet isolation and allotransplantation in 22 consecutive cases. Transplantation (1992) 2.20

Three years clinical experience with intestinal transplantation. J Am Coll Surg (1994) 2.20

Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts. Gastroenterology (1999) 2.19

Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl Surg (1997) 2.16

A critical appraisal of methods to grade transplant glomerulitis in renal allograft biopsies. Am J Transplant (2010) 2.14

Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clin Infect Dis (1996) 2.12

One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults. Transplant Proc (1991) 2.10

A prospective randomized trial of FK506-based immunosuppression after renal transplantation. Transplantation (1995) 2.09

The side effects of FK 506 in humans. Transplant Proc (1990) 2.08

Randomised trialomania? The multicentre liver transplant trials of tacrolimus. Lancet (1995) 2.04

Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation. J Am Coll Surg (1998) 1.99

Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in rats using FK506. Transplantation (1991) 1.95

Successful hamster-to-rat liver xenotransplantation under FK506 immunosuppression induces unresponsiveness to hamster heart and skin. Transplantation (1993) 1.94

FK 506 in steroid-resistant focal sclerosing glomerulonephritis of childhood. Lancet (1990) 1.94

Solid tumors after heart transplantation: lethality of lung cancer. Ann Thorac Surg (1995) 1.92

Acute liver failure: clinical features, outcome analysis, and applicability of prognostic criteria. Liver Transpl (2000) 1.88

Growth of donor-derived dendritic cells from the bone marrow of murine liver allograft recipients in response to granulocyte/macrophage colony-stimulating factor. J Exp Med (1995) 1.88

Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: the role of primary infection. J Infect Dis (1985) 1.88

Costimulatory molecule-deficient dendritic cell progenitors (MHC class II+, CD80dim, CD86-) prolong cardiac allograft survival in nonimmunosuppressed recipients. Transplantation (1996) 1.86

Experience with liver and kidney allografts from non-heart-beating donors. Transplantation (1995) 1.83

Specificity of alloactivated human T lymphocyte clones in secondary proliferation, cell-mediated lympholysis and interleukin-2 release. J Immunogenet (1985) 1.82

Orthotopic liver transplantation in the mouse. Transplantation (1991) 1.82

Apoptosis within spontaneously accepted mouse liver allografts: evidence for deletion of cytotoxic T cells and implications for tolerance induction. J Immunol (1997) 1.81

Pathologic observations in human allograft recipients treated with FK 506. Transplant Proc (1990) 1.80

Early events in liver allograft rejection. Delineation of sites of simultaneous intragraft and recipient lymphoid tissue sensitization. Am J Pathol (1991) 1.78

Use of FK 506 in pediatric patients. Transplant Proc (1991) 1.77

Randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone after renal transplantation: preliminary report. Transplant Proc (1993) 1.72

Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporine and prednisone. Circulation (1987) 1.71

Transplantation. JAMA (1990) 1.71

Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation (1999) 1.70

Status and prospects for success of the endangered species act: a look at recovery plans. Science (1993) 1.68

Early Function of Heart, Liver, and Kidney Allografts Following Combined Procurement. Transplant Proc (1984) 1.66

Acute experimental silicosis. Lung morphology, histology, and macrophage chemotaxin secretion. Am J Pathol (1982) 1.61

Histocompatibility and liver transplant outcome. Does HLA exert a dualistic effect? Transplantation (1988) 1.61

Incidence and risk factors associated with the development of cytomegalovirus disease after intestinal transplantation. Transplantation (1995) 1.59

Weaning of immunosuppression in long-term liver transplant recipients. Transplantation (1995) 1.59

The spectrum of portal vein thrombosis in liver transplantation. Ann Surg (1991) 1.58